Trial Profile
Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 06 Aug 2014 The European Commission has approved simoctocog alfa for the treatment and prophylaxis of bleeding in patients with haemophilia A based on the results of GENA-01, GENA-03 and GENA-08, according to an Octapharma media release.
- 01 Apr 2014 New trial record